Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
StatementNovartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
StatementNovartis provides support for Moroccan earthquake victims
StatementGT005 (PPY988): Development Program in Geographic Atrophy
StatementNovartis statement on filing of Inflation Reduction Act lawsuit
StatementNovartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
StatementNovartis releases emergency funding of USD 1 million for people in Turkey and Syria, and launches employee donation and volunteering programs